Big biotech Celgene (CELG) rolled out more data on its new drug for Crohn’s disease Tuesday, sending Celgene shares up 3% in the stock market today. On Monday, Celgene released the abstract on the phase two trial of GED-0301, also called Mongersen, which showed good results for patients after two weeks of taking the drug. On Tuesday, it presented the full data at the United European Gastroenterology Week in Vienna, revealing that four-week and
Big biotech Celgene (CELG) rolled out more data on its new drug for Crohn’s disease Tuesday, sending Celgene shares up 3% in the stock market today. On Monday, Celgene released the abstract on the phase two trial of GED-0301, also called Mongersen, which showed good results for patients after two weeks of taking the drug. On Tuesday, it presented the full data at the United European Gastroenterology Week in Vienna, revealing that four-week and
Big biotech Celgene (CELG) announced Monday that it will present data on its Crohn’s disease drug GED-0301 at a conference Tuesday, after posting an abstract with top-line results on the high side of expectations. Celgene stock was up 2.5% in morning trading on the stock market today. The drug is a potential blockbuster. The phase-two trial compared three different doses of the drug, also called Mongersen, with a group taking a placebo. After two